Progression‐free survival assessed per immune‐related or conventional response criteria, which is the better surrogate endpoint for overall survival in trials of immune‐checkpoint inhibitors in lung cancer: A systematic review and meta‐analysis

Abstract Progression‐free survival (PFS) has been used as a surrogate endpoint for overall survival (OS) in lung cancer trials. The pattern of response to immune‐checkpoint inhibitors (ICIs) differs from that to conventional chemotherapy, so immune‐related response evaluation criteria were proposed....

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Guang‐Li Zhu, Kai‐Bin Yang, Si‐Qi Tang, Liang Peng
Formato:	article
Lenguaje:	EN
Publicado:	Wiley 2021
Materias:	immune‐checkpoint inhibitors lung cancer progression‐free survival surrogate endpoints Neoplasms. Tumors. Oncology. Including cancer and carcinogens RC254-282
Acceso en línea:	https://doaj.org/article/453ad8aa9af1416885e7badeae00b796
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:453ad8aa9af1416885e7badeae00b796
record_format	dspace
spelling	oai:doaj.org-article:453ad8aa9af1416885e7badeae00b7962021-12-01T04:49:14ZProgression‐free survival assessed per immune‐related or conventional response criteria, which is the better surrogate endpoint for overall survival in trials of immune‐checkpoint inhibitors in lung cancer: A systematic review and meta‐analysis2045-763410.1002/cam4.4347https://doaj.org/article/453ad8aa9af1416885e7badeae00b7962021-12-01T00:00:00Zhttps://doi.org/10.1002/cam4.4347https://doaj.org/toc/2045-7634Abstract Progression‐free survival (PFS) has been used as a surrogate endpoint for overall survival (OS) in lung cancer trials. The pattern of response to immune‐checkpoint inhibitors (ICIs) differs from that to conventional chemotherapy, so immune‐related response evaluation criteria were proposed. This study aims at determining which PFS measure, PFS assessed per immune‐related response evaluation criteria (iPFS), or conventional criteria (cPFS), is the better surrogate endpoint for OS in trials of ICIs in lung cancer. We selected clinical trials in lung cancer that administered ICIs to at least one arm and reported both median OS and median PFS from PubMed, Embase, and The Cochrane Library. We compared the correlation between treatment effect (hazard ratio) on OS and cPFS or iPFS and the correlation between median OS and median cPFS or iPFS using weighted linear regression at trial level. We analyzed 78 ICI arms (13,438 patients) from 54 studies, including 66 arms with cPFS, seven arms with iPFS, and five arms with both kinds of PFS. We demonstrated an excellent correlation between treatment effect (hazard ratio) on OS and iPFS (RWLS2 = 0.91), while the correlation was moderate for cPFS (RWLS2 = 0.38). Similarly, the correlation between median OS and median iPFS was also strong (RWLS2 ranging from 0.86 to 0.96) across different phases of trials and different types of lung cancer, ICI, and treatment modalities, while it was much weaker for median cPFS (RWLS2 ranging from 0.28 to 0.88). In conclusion, iPFS provides better trial‐level surrogacy for OS than cPFS in trials of ICIs in lung cancer.Guang‐Li ZhuKai‐Bin YangSi‐Qi TangLiang PengWileyarticleimmune‐checkpoint inhibitorslung cancerprogression‐free survivalsurrogate endpointsNeoplasms. Tumors. Oncology. Including cancer and carcinogensRC254-282ENCancer Medicine, Vol 10, Iss 23, Pp 8272-8287 (2021)
institution	DOAJ
collection	DOAJ
language	EN
topic	immune‐checkpoint inhibitors lung cancer progression‐free survival surrogate endpoints Neoplasms. Tumors. Oncology. Including cancer and carcinogens RC254-282
spellingShingle	immune‐checkpoint inhibitors lung cancer progression‐free survival surrogate endpoints Neoplasms. Tumors. Oncology. Including cancer and carcinogens RC254-282 Guang‐Li Zhu Kai‐Bin Yang Si‐Qi Tang Liang Peng Progression‐free survival assessed per immune‐related or conventional response criteria, which is the better surrogate endpoint for overall survival in trials of immune‐checkpoint inhibitors in lung cancer: A systematic review and meta‐analysis
description	Abstract Progression‐free survival (PFS) has been used as a surrogate endpoint for overall survival (OS) in lung cancer trials. The pattern of response to immune‐checkpoint inhibitors (ICIs) differs from that to conventional chemotherapy, so immune‐related response evaluation criteria were proposed. This study aims at determining which PFS measure, PFS assessed per immune‐related response evaluation criteria (iPFS), or conventional criteria (cPFS), is the better surrogate endpoint for OS in trials of ICIs in lung cancer. We selected clinical trials in lung cancer that administered ICIs to at least one arm and reported both median OS and median PFS from PubMed, Embase, and The Cochrane Library. We compared the correlation between treatment effect (hazard ratio) on OS and cPFS or iPFS and the correlation between median OS and median cPFS or iPFS using weighted linear regression at trial level. We analyzed 78 ICI arms (13,438 patients) from 54 studies, including 66 arms with cPFS, seven arms with iPFS, and five arms with both kinds of PFS. We demonstrated an excellent correlation between treatment effect (hazard ratio) on OS and iPFS (RWLS2 = 0.91), while the correlation was moderate for cPFS (RWLS2 = 0.38). Similarly, the correlation between median OS and median iPFS was also strong (RWLS2 ranging from 0.86 to 0.96) across different phases of trials and different types of lung cancer, ICI, and treatment modalities, while it was much weaker for median cPFS (RWLS2 ranging from 0.28 to 0.88). In conclusion, iPFS provides better trial‐level surrogacy for OS than cPFS in trials of ICIs in lung cancer.
format	article
author	Guang‐Li Zhu Kai‐Bin Yang Si‐Qi Tang Liang Peng
author_facet	Guang‐Li Zhu Kai‐Bin Yang Si‐Qi Tang Liang Peng
author_sort	Guang‐Li Zhu
title	Progression‐free survival assessed per immune‐related or conventional response criteria, which is the better surrogate endpoint for overall survival in trials of immune‐checkpoint inhibitors in lung cancer: A systematic review and meta‐analysis
title_short	Progression‐free survival assessed per immune‐related or conventional response criteria, which is the better surrogate endpoint for overall survival in trials of immune‐checkpoint inhibitors in lung cancer: A systematic review and meta‐analysis
title_full	Progression‐free survival assessed per immune‐related or conventional response criteria, which is the better surrogate endpoint for overall survival in trials of immune‐checkpoint inhibitors in lung cancer: A systematic review and meta‐analysis
title_fullStr	Progression‐free survival assessed per immune‐related or conventional response criteria, which is the better surrogate endpoint for overall survival in trials of immune‐checkpoint inhibitors in lung cancer: A systematic review and meta‐analysis
title_full_unstemmed	Progression‐free survival assessed per immune‐related or conventional response criteria, which is the better surrogate endpoint for overall survival in trials of immune‐checkpoint inhibitors in lung cancer: A systematic review and meta‐analysis
title_sort	progression‐free survival assessed per immune‐related or conventional response criteria, which is the better surrogate endpoint for overall survival in trials of immune‐checkpoint inhibitors in lung cancer: a systematic review and meta‐analysis
publisher	Wiley
publishDate	2021
url	https://doaj.org/article/453ad8aa9af1416885e7badeae00b796
work_keys_str_mv	AT guanglizhu progressionfreesurvivalassessedperimmunerelatedorconventionalresponsecriteriawhichisthebettersurrogateendpointforoverallsurvivalintrialsofimmunecheckpointinhibitorsinlungcancerasystematicreviewandmetaanalysis AT kaibinyang progressionfreesurvivalassessedperimmunerelatedorconventionalresponsecriteriawhichisthebettersurrogateendpointforoverallsurvivalintrialsofimmunecheckpointinhibitorsinlungcancerasystematicreviewandmetaanalysis AT siqitang progressionfreesurvivalassessedperimmunerelatedorconventionalresponsecriteriawhichisthebettersurrogateendpointforoverallsurvivalintrialsofimmunecheckpointinhibitorsinlungcancerasystematicreviewandmetaanalysis AT liangpeng progressionfreesurvivalassessedperimmunerelatedorconventionalresponsecriteriawhichisthebettersurrogateendpointforoverallsurvivalintrialsofimmunecheckpointinhibitorsinlungcancerasystematicreviewandmetaanalysis
_version_	1718405719705780224

Progression‐free survival assessed per immune‐related or conventional response criteria, which is the better surrogate endpoint for overall survival in trials of immune‐checkpoint inhibitors in lung cancer: A systematic review and meta‐analysis

Ejemplares similares